Biomedical Occupation or Discipline – Page 34

Sands Capital Successfully Raises $555 Million for Third Life Sciences Venture Fund

1 year ago talkbio0Tagged Biotechnology, Capital, Health care facility, healthcare innovation, Investments, medical technology, Sand, venture fund

Sands Capital, life sciences, venture fund, fundraising, healthcare investments, biotechnology, medical technology, pharmaceuticals, healthcare innovation.

Revolutionizing Pharmaceuticals: Nabla Bio Secures $26M for AI-Powered Protein Design

1 year ago talkbio0Tagged Artificial Intelligence, Biotechnology, Drug Discovery, generative, Nabla Bio, pharmaceutical partners, protein design

Nabla Bio, generative AI, protein design, funding, pharmaceutical partners, biotechnology, drug discovery.

AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership

1 year ago talkbio0Tagged AbbVie, Drug Development, Gilgamesh, Hallucinogens, Mental disorders, mental health, Neuroscience discipline, next-generation

AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.

Ajax Pharmaceuticals Secures $95 Million for JAK Inhibitor Drug Development

1 year ago talkbio0Tagged Autoimmune Diseases, Drug Development, Inflammatory disorder, inhibitors, Investments, Janus kinase

Ajax Pharmaceuticals, JAK inhibitors, drug development, funding, investment, inflammatory diseases, autoimmune disorders, cancer.

Lilly-backed Lycia Therapeutics Secures $106M for Clinical Trials on Lysosomal Protein Degraders

1 year ago talkbio0Tagged Biotechnology, Clinical Trials, Drug Development, Eli, Eli Lilly, Lycia Therapeutics, lysosomal protein

Lycia Therapeutics, Eli Lilly, lysosomal protein degraders, clinical trials, funding, biotechnology, drug development

Maze Therapeutics Secures New Partnership for Pompe Drug Development After Sanofi Deal Collapse

1 year ago talkbio0Tagged amsacrine/azacitidine/etoposide, Deal Collapse, Drug Development, Hereditary Diseases, Partnership, Pompe drug, sanofi

Maze Therapeutics, Pompe drug, partnership, Sanofi deal collapse, drug development, genetic diseases

Revolutionizing Healthcare: Streamlining Cell and Gene Therapy Manufacturing (Part 1)

1 year ago talkbio0Tagged Biotechnology, Cell Therapy, Cost Effectiveness, gene therapy, healthcare innovation, Manufacture, Precision Medicine, production, regulatory, scalability

Cell therapy, gene therapy, manufacturing, biotechnology, healthcare innovation, personalized medicine, production challenges, regulatory compliance, scalability, cost-effectiveness.